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Objectives: COPD exacerbations are associated with significant morbidity and mortality. This
randomized, double-blind, parallel-group, multicenter study evaluated the effect of flutica-
sone propionate/salmeterol 250/50 and salmeterol 50 mg twice daily on moderate to severe
exacerbations.
Methods: Patients received standardized treatment with fluticasone propionate/salmeterol
250/50 during a 1-month run-in, followed by randomization to fluticasone propionate/salme-
terol 250/50 or salmeterol for 12 months. Moderate to severe exacerbations were defined as
worsening symptoms of COPD requiring treatment with oral corticosteroids, antibiotics, or
hospitalization.
Results: In 782 patients with COPD (mean FEV1Z 0.94  0.36 L, 33% predicted normal), treat-
ment with fluticasone propionate/salmeterol 250/50 significantly reduced (1) the annual rate
of moderate to severe exacerbations by 30.5% compared with salmeterol (1.06 and 1.53 per
subject per year, respectively, p < 0.001), (2) the risk of time to first exacerbation by 25% (haz-
ard ratioZ 0.750, pZ 0.003) and (3) the annual rate of exacerbations requiring oral cortico-
steroids by 40% (p < 0.001). Clinical improvements observed during run-in treatment with
fluticasone propionate/salmeterol 250/50 were better maintained over 12 months with flutica-
sone propionate/salmeterol 250/50 than salmeterol. Adverse events were reported fortive pulmonary disease; FEV1, forced expiratory volume in one second; FSC, fluticasone propionate/
vital capacity.
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1100 G.T. Ferguson et al.a similar percentage of subjects across groups. A higher reporting of pneumonia was observed
with fluticasone propionate/salmeterol 250/50 than salmeterol (7% vs. 4%).
Conclusions: We conclude that fluticasone propionate/salmeterol 250/50 is more effective
than salmeterol at reducing the rate of moderate to severe exacerbations over 1 year. The
benefits of this reduction relative to the risk of a higher incidence of reported pneumonia
should be considered. This study supports the use of fluticasone propionate/salmeterol
250/50 for the reduction of COPD exacerbations in patients with COPD.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is an inflam-
matory disease of the airways characterized by progressive
airflow limitation that is not fully reversible, with commonly
reported symptoms of dyspnea, sputum production and
cough.1 Exacerbations of COPD, although highly variable in
clinical presentation, are generally recognized as an acute
worsening of symptoms beyond normal day to day variation
that warrant a change in disease management.1,2
Increasing frequency of COPD exacerbations is associated
with greater impairment in quality of life, an increased rate
of decline in lung function, and increased mortality.3e7 More
severe airflow obstruction, advanced age, and a history of
prior exacerbations are important independent risk factors
for both COPD exacerbations and hospitalizations due to
exacerbations.8 Due to the substantial impact that exacer-
bations have on patients who suffer from them, the preven-
tion and treatment of COPD exacerbations is recognized as
a key goal in COPD disease management.1,2
Treatment of patients with COPD with fluticasone pro-
pionate (FP) 500 mg and salmeterol 50 mg together in a single
inhaler (FSC 500/50) twice daily has been shown in several
studies to significantly reduce the annualized rate of exac-
erbations in patients with COPD compared with salmeterol,
FP, and placebo.9e11 Studies of FSC with a lower dose of FP
(250 mg) have demonstrated the benefit of FSC 250/50
twice daily on measures of lung obstruction and hyperinfla-
tion, symptoms, and exercise endurance time in COPD.12e15
However, the effect of FSC 250/50 on exacerbations is not
well characterized.
This clinical trial was designed to evaluate the effect of
FSC 250/50 on moderate to severe exacerbations in
patients with COPD and who had a history of prior
exacerbations. Salmeterol was chosen as the comparison
arm to evaluate the benefit of the FP component of FSC
250/50 over a long-acting bronchodilator alone.
Methods
Patients
Patients were 40 years of age or older with a diagnosis of
COPD,16 a cigarette smoking history of greater than or
equal to 10 pack-years, a pre-albuterol FEV1/FVC of 0.70
or less, a FEV1 of 50% of predicted normal or less and a his-
tory of 1 or more exacerbations of COPD in the year prior to
the study that required treatment with oral corticosteroids,
antibiotics, or hospitalization. Patients were excluded if
they had a diagnosis of asthma, a significant lung diseaseother than COPD, a clinically significant and uncontrolled
medical disorder including but not limited to cardiovascu-
lar, endocrine or metabolic, neurological, psychiatric, he-
patic, renal, gastric, and neuromuscular diseases, or had
a COPD exacerbation that was not resolved at screening.
Study design
This was a randomized, double-blind, parallel-group study
(study code SCO40043) conducted at 94 research sites in the
United States and Canada. For each site, an institutional
review board or ethics committee approved the study and all
patients provided written informed consent prior to conduct
of study procedures. Patients completed a 4-week run-in
period during which they received open-label FP/salmeterol
250/50 via DISKUS (FSC; Advair, Seretide, GlaxoSmithKline,
Research Triangle Park, NC, USA) twice daily. Following run-
in, patients were randomized to FSC 250/50 or salmeterol
50 mg (Serevent; GlaxoSmithKline) twice daily via DISKUS
for 12 months. Clinic visits were conducted at screening,
day 1 (randomization), and after 4, 8, 12, 20, 28, 36, 44,
and 52 weeks of treatment. Treatments were assigned in
blocks using a center based randomization schedule. Bron-
chodilator response to FSC DISKUS 250/50 is generally larger
in subjects with COPD who demonstrate FEV1 reversibility to
albuterol compared with non-reversible subjects.12 There-
fore, for evaluation of FEV1, patients were stratified based
onFEV1 response toalbuterol at screening toprovidea similar
distribution of albuterol-responsive and non-responsive pa-
tients in each group. Albuterol-responsive was defined as
an increase in FEV1 of 200 mL and 12% from baseline fol-
lowing inhalation of four puffs of albuterol. As-needed albu-
terol was provided for use throughout the study. The use of
concurrent inhaled long-acting bronchodilators (beta2-ago-
nist and anticholinergic), ipratropium/albuterol combina-
tion products, oral beta-agonists, inhaled corticosteroids,
and theophylline preparations were not allowed during the
treatment period. Oral corticosteroids and antibiotics were
allowed for the acute treatment of COPD exacerbations.
Measurements
The primary efficacy endpoint was the annual rate of
moderate to severe exacerbations. Secondary endpoints
were the time to first moderate to severe exacerbation,
the annual rate of exacerbations requiring oral corticoste-
roids, and pre-dose FEV1. Related endpoints were the annual
rate of all exacerbations (mild and moderate to severe),
duration of moderate to severe exacerbations, time to onset
of each moderate to severe exacerbation, exacerbation
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and antibiotic courses and hospital stays) and diary records
of dyspnea, nighttime awakenings due to COPD, and use of
supplemental albuterol. Spirometry was obtained using cen-
tralized spirometry services provided by the Compleware
Corporation (North Liberty, IA, USA).
Patients recorded daily on diary cards morning peak flow
measurements, nighttime awakenings, albuterol use, and
symptom ratings of major and minor symptoms. Major
symptoms were defined as dyspnea, sputum purulence,
and sputum volume, and minor symptoms were defined as
cough/wheeze, fever, sore throat, and cold (nasal dis-
charge/congestion).3,17 Dyspnea, sputum purulence and
volume, and cough/wheeze were evaluated relative to
their usual state while others were evaluated based on
their absence or presence. Dyspnea was rated using a 5
point scale where 2Z much less than usual, 1Z less
than usual, 0Z same as usual, 1Z more than usual, and
2Z much more than usual, while sputum purulence and
volume, and cough/wheeze were rated using a 2 point scale
where 0Z usual level and 1Z increased level.
A COPD exacerbation was defined as worsening of two or
more major symptoms or one major and one minor
symptom for two or more consecutive days.3,17 Moderate
to severe exacerbations were defined as worsening respira-
tory symptoms as described above requiring treatment with
oral corticosteroids, antibiotics, or hospitalization. Mild ex-
acerbations did not require these interventions. Subjects
were instructed to contact their study investigator or coor-
dinator if they experienced worsening symptoms of COPD
and to report to their study site as required for evaluation.
Study investigators assessed the severity of the worsening
symptoms to determine the need for additional treatment.
If additional treatment beyond blinding study medication or
short-acting bronchodilators was required, investigators
were instructed to treat the exacerbation with a course
of antibiotics and/or oral corticosteroids. Courses of antibi-
otics were to be 7e14 days in duration with provisions
allowed for additional courses if first line treatment failed.
Use of antibiotics for treatment of upper or lower respira-
tory tract infections was not considered an exacerbation
unless accompanied by worsening symptoms of COPD.
Courses of oral corticosteroids were not to exceed 14 days
unless given approval by the study sponsor. Any course of
antibiotics or oral corticosteroids starting within 7 days of
the stop date for a previous course was considered treat-
ment of a single exacerbation.
Health status was evaluated using the St. George’s
Respiratory Questionnaire administered at study visits at
day 1, and weeks 12, 28, and 52.18 Safety was assessed by
adverse event reporting.
Statistical analysis
Statistical analyses were performed using SAS version 8.2
software in a UNIX reporting environment. The primary
analysis of the rate of moderate to severe exacerbations
compared treatment groups using a negative binomial
regression model. The negative binomial regression model
including terms for baseline disease severity, investigator,
reversibility stratum, treatment group and time on treat-
ment, incorporated modeling of the variability betweensubjects in the estimation of exacerbation rates, thereby
reducing bias caused by study withdrawals.19
The planned enrollment for this study (NZ 740) pro-
vided 90% power to detect a >20% reduction in the rate
of moderate/severe exacerbations in the FSC 250/50 treat-
ment group compared with the salmeterol treatment group
at the 0.05 significance level using unadjusted annual exac-
erbation rate estimates of 1.9 and 1.5 for salmeterol and
FSC 250/50, respectively. Time to first moderate to severe
exacerbation was summarized by treatment group and pre-
sented graphically with KaplaneMeier curves. The hazard
ratio for the treatment comparison of time to first moder-
ate to severe exacerbation was derived from a Cox’s pro-
portional hazards model with terms for baseline disease
severity, investigator, reversibility stratum and treatment
group in the model. Time to each moderate to severe exac-
erbation was compared between treatment groups using an
AndersoneGill model for time to recurrent events.
The primary analysis of pre-dose AM FEV1 was mean
change from baseline compared between treatment groups
at endpoint. Endpoint was defined as the last scheduled
measurement of pre-dose AM FEV1 during the 52-week
treatment period and baseline was defined as the pre-dose
AM FEV1 measure from day 1 (randomization). An analysis
of covariance (ANCOVA) model including terms for treat-
ment group, investigator, reversibility stratum and baseline
was used to test statistical differences between treatment
groups. An ANCOVA model was also used to test statistical
differences in treatment group mean changes from baseline
for the overall 52-week treatment period for shortness of
breath scores and values for supplemental albuterol use
and nighttime awakenings due to COPD.
Results
Patients
Of the 1262 patients screened, 480 were excluded at
screening or during run-in, and 782 were randomized of
whom 516 (66%) completed the study (Fig. 1). The efficacy
and health outcomes data for 6 patients from one investiga-
tional site were unevaluable due to poor clinical practices
and were excluded from the analysis. Exclusion of these
data did not affect the efficacy analyses. A total of 277 of
394 (70%) patients in the FSC 250/50 group completed the
study compared with 239 of 388 (62%) patients in the salme-
terol group. The probability of subjects withdrawing from
the study during the 52-week treatment period is shown
in Fig. 2. At week 13, a total of 70 (18%) subjects were with-
drawn from the salmeterol group compared with 36 (9%)
subjects in the FSC 250/50 group. Thereafter, the differ-
ence in the percentage of subjects who were withdrawn
from the study was similar between groups. The probability
of withdrawing from the study at any time was significantly
greater in the salmeterol group compared with FSC 250/50
(pZ 0.003). The most common reasons for withdrawal in
the FSC 250/50 and salmeterol groups were patient decision
to withdraw (9% and 10%) and adverse event (7% and 9%).
Demographic data, smoking history and baseline lung func-
tion values, and prior medication use were similar between
groups (Table 1). Patients were predominately white (93%)
1262 Patients screened for 
eligibility
480 (38%) Excluded at screening/ run-in
338 entry criteria not met
55 consent withdrawn
15 exacerbation
13 protocol violation
12 lost to follow-up
12 non-compliance
11 adverse event
24 Other reasons
782 Patients randomized
394 Assigned to 
FSC 250/50
277 (70%) Completed 
the study
117 (30%) Withdrew
37 patient decision 
26 adverse event
16 lack of efficacy
10 exacerbation
10 lost of follow-up
7 protocol violation
11 other reasons
388 Assigned to 
salmeterol
239 (62%) Completed
the study 
149 (38%) Withdrew
37 patient decision   
33 adverse event
23 lack of efficacy
21 exacerbation
10 lost of follow-up
7 protocol violation
18 other reasons
Figure 1 Study flow diagram.
1102 G.T. Ferguson et al.with severe airway obstruction (mean pre-albuterol FEV1 of
32.8% of predicted normal) and the majority (56%) were us-
ing inhaled corticosteroids or an inhaled corticosteroid/
long-acting beta2-agonist combination at screening.394Number 335343351363370389
388at Risk 297306309327352379
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Table 1 Demography and baseline characteristics
Characteristic FSC 250/50
(NZ 394)
Salmeterol
(NZ 388)
Age, years 64.9  9.0 65.0  9.1
Male, % 58 52
Race, %
White 94 93
Black 4 6
Other 2 1
Body mass index, kg/m2 27.3  6.2 27.7  7.4
Current smoker, % 40 38
Smoking history, pack-years 58.5  30.6 54.4  25.7
Pre-bronchodilator FEV1, L 0.95  0.36 0.93  0.35
Pre-bronchodilator FEV1, % predicted 32.8  11.0 32.8  10.1
Post-bronchodilator FEV1, L 1.15  0.47 1.15  0.54
Post-bronchodilator FEV1, % predicted 39.8  13.9 40.6  15.4
Albuterol responsive/non-responsive, % 42/58 41/59
Pre-bronchodilator FVC, L 2.16  0.75 2.14  0.75
Pre-bronchodilator FEV1/FVC 0.44  0.11 0.44  0.11
Previous medication use, %
Ipratropium 8 10
Ipratropium/albuterol combination 33 31
Tiotropium 14 10
Short-acting beta2-agonists 48 45
Long-acting beta2-agonists 12 11
Long-acting beta2-agonists/inhaled
corticosteroid combination
42 40
Inhaled corticosteroids 15 18
Theophylline 6 8
Anti-leukotrienes 5 4
FEV1, forced expiratory volume in one second; FVC, forced vital capacity; L, liters; FSC 250/50, fluticasone propionate/salmeterol
250/50 twice daily. All values are presented as absolute numbers or means  SD.
Fluticasone propionate/salmeterol vs salmeterol for COPD exacerbations 1103with 1.53 per patient with salmeterol (p < 0.001), corre-
sponding to a treatment ratio of 0.695 (95% CI 0.58e0.83)
and a 30.5% reduction in the mean annual rate of exacerba-
tions (Table 2). A total of 54% and 60% of patients experi-
enced at least 1 moderate/severe exacerbation over the
duration of the study in the FSC 250/50 and salmeterol
groups, respectively (Table 2). For the mean annual rate
of exacerbations requiring oral corticosteroids, the treat-
ment ratio for FSC 250/50 compared with salmeterol was
0.603, representing a 40% reduction with FSC 250/50 treat-
ment (p < 0.001, Table 2). The mean annual rate of all
exacerbations (mild plus moderate to severe) was signifi-
cantly lower with FSC 250/50 treatment (treatment ratio
of 0.83, pZ 0.002, Table 2).
The time to first moderate to severe exacerbation was
significantly delayed in patients treated with FSC 250/50
compared with salmeterol, with a hazard ratio of 0.75,
corresponding to a risk reduction of 25% (95% CI 0.62e0.91,
pZ 0.003, Fig. 3). FSC 250/50 also significantly lowered
the risk of experiencing recurrent exacerbations by 25%
compared with salmeterol (hazard ratio 0.75, 95% CI
0.63e0.88, p < 0.001).
The mean duration of all moderate to severe exacerba-
tions was similar (23.0 and 21.3 days in the FSC 250/50 and
salmeterol groups, respectively) as was the mean recoverytime (ranging from 16.2 to 25.7 days for both treatment
groups).
The most commonly reported cause of exacerbation, as
identified by investigators, was respiratory infection of the
upper or lower airways, reported for 49% of all moderate to
severe exacerbations. Additional causes were unknown
etiology (26%), environmental factors of air pollution, to-
bacco smoke, and cold air (6%), allergy (5%), use of non-
steroidal anti-inflammatory medications (3%), withholding
COPDmedications (2%), stress/emotions (2%), and other (7%).
Lung function
During run-in, treatment with open-label FSC 250/50 signif-
icantly increased mean morning FEV1 from screening levels
(increases of 114  15 mL and 118  16 mL, in patients sub-
sequently randomized to FSC 250/50 and salmeterol, respec-
tively, p < 0.001 for within group change from screening,
Fig. 4). Following randomization, pre-dose FEV1 decreased
over the 52-week treatment period in both groups. The de-
crease in FEV1 was significantly larger in the salmeterol
group (82  17 mL, p < 0.001 for within group change
from treatment day 1) compared with the FSC 250/50 group
(12  23 mL, pZ 0.592, for within group change from
treatment day 1). Mean differences in pre-dose FEV1 of
Table 2 COPD exacerbations
FSC 250/50
(NZ 391)
Salmeterol
(NZ 385)
Patients with 1 moderate/severe exacerbation, n (%) 211 (54) 230 (60)
Total number of moderate/severe exacerbations 368 432
Mean annual rate of moderate/severe exacerbations 1.06 1.53
Treatment ratio for FSC 250/50 vs. salmeterol 0.695
95% confidence interval 0.58, 0.83
p-value <0.001
Patients with 1 OCS-treated exacerbation, n (%) 150 (38) 166 (43)
Total number of OCS-treated exacerbations 231 289
Mean annual rate of OCS-treated exacerbations 0.66 1.09
Treatment ratio for FSC 250/50 vs. salmeterol 0.603
95% confidence interval 0.47, 0.77
p-value <0.001
Patients with any exacerbations (mild and moderate/severe) 343 (88) 335 (87)
Total number of all exacerbations 1590 1618
Mean annual rate of all exacerbations 4.82 5.78
Treatment ratio for FSC 250/50 vs. salmeterol 0.833
95% confidence interval 0.74, 0.94
p-value 0.002
OCS, oral corticosteroids; FSC 250/50, fluticasone propionate/salmeterol 250/50 twice daily; moderate/severe exacerbations, worsen-
ing symptoms requiring treatment with OCS, antibiotics, and/or hospitalization; mild exacerbations, worsening symptoms that were
self-managed by patient and did not require OCS or antibiotic treatment.
1104 G.T. Ferguson et al.47  23 mL and 74  27 mL at endpoint andweek 52, respec-
tively, significantly favored FSC 250/50 over salmeterol
(p  0.04).
Supplemental albuterol use
Mean baseline use of supplemental albuterol was 4.7  0.23
and 5.0  0.24 puffs per day for patients randomized to FSC
250/50 and salmeterol, respectively. Over weeks 1e52, sal-
meterol-treated patients had a significantly larger mean in-
crease in supplemental albuterol use (0.8  0.13 puffs/day)391Number
at Risk
329 283 259 236 220 20
385 293 244 215 192 174 15
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Figure 3 KaplaneMeier estimates of the time to first moderate t
dashed line represents salmeterol.compared with FSC 250/50 treated patients (0.4  0.12
puffs/day, pZ 0.009).
Patients’ symptoms
Shortness of breath
Increases in dyspnea scores were significantly greater with
salmeterol than with FSC 250/50. Diary dyspnea scores
increased by 0.12  0.03 and 0.21  0.03 units over weeks
1e52 with FSC 250/50 and salmeterol, respectively, repre-
senting a mean difference of 0.10  0.03 units, pZ 0.001).Fluticasone propionate/salmeterol 250/50
Salmeterol
p=0.003 vs. Salmeterol
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Figure 4 Change from baseline (randomization) for morning pre-dose FEV1 compared with screening, over the 52-week treat-
ment period, and at endpoint. *pZ 0.04, FSC 250/50 vs. salmeterol at endpoint. EP, endpoint.
Table 3 Adverse events reported for >5% of patients in
either group
Adverse event FSC 250/50
(NZ 394)
Salmeterol
(NZ 388)
Any event, n (%) 347 (88) 334 (86)
Nasopharyngitis 151 (38) 141 (36)
Pharyngolaryngeal pain 137 (35) 138 (36)
Pyrexia 74 (19) 68 (18)
Headache 45 (11) 46 (12)
COPD 38 (10) 46 (12)
Rhinorrhea 39 (10) 45 (12)
Nasal congestion 34 (9) 36 (9)
Upper respiratory
tract infection
31 (8) 31 (8)
Pneumonias 29 (7) 15 (4)
Diarrhea 24 (6) 25 (6)
Back pain 23 (6) 23 (6)
Sinusitis 28 (7) 17 (4)
Cough 14 (4) 25 (6)
FSC 250/50, fluticasone propionate/salmeterol 250/50 twice
daily.
Fluticasone propionate/salmeterol vs salmeterol for COPD exacerbations 1105Nighttime awakenings
The a priori analysis of nighttime awakenings due to COPD
was for the subset of symptomatic subjects that reported at
least one nighttime awakening during the 7 days prior to
randomization. At baseline, 151 (39%) and 152 (39%) sub-
jects in the FSC 250/50 and salmeterol groups, respec-
tively, reported a nighttime awakening due to COPD with
mean values of 6.72  0.49 and 5.95  0.47 awakenings
per week. FSC 250/50 treatment significantly decreased
the mean number of nighttime awakenings by
1.12  0.35 awakenings per week compared with an in-
crease of 0.42  0.37 awakenings per week in the salme-
terol group (mean difference of 1.33 awakenings per
week, pZ 0.009).
Health-related quality of life
In both treatment groups, there was a worsening in mean
SGRQ total score from baseline to endpoint with a signifi-
cantly larger change in the salmeterol group (3.49 units)
compared with the FSC 250/50 group (1.86 units, mean
difference of 1.86 units, pZ 0.035). The change from
baseline in SGRQ score observed for the treatment groups
and the mean difference in score between groups did not
meet the threshold of 4 units defined as a clinically mean-
ingful difference.18 Mean differences between FSC 250/50
and salmeterol for domain scores were 2.8  1.39 for
symptoms (pZ 0.045), 1.96  1.05 for impacts
(pZ 0.063), 1.64  1.01 for activity (pZ 0.104).
Safety
Adverse events were reported for a similar percentage of
subjects in the FSC 250/50 (88%) and salmeterol (86%)
groups. The most common adverse events across both
groups were nasopharyngitis and pharyngolaryngeal pain
which occurred in a similar percentage of subjects in eachgroup (35e38% of subjects). Adverse events that occurred
in greater than 5% of subjects in any group are reported in
Table 3.
A total of 22% and 20% of patients experienced non-fatal
serious adverse events in the FSC 250/50 and salmeterol
groups, respectively. The most common serious adverse
event was worsening COPD which occurred in 9% and 10% of
subjects in the FSC 250/50 and salmeterol groups, re-
spectively. There were 6 deaths in the FSC 250/50 group
and 3 deaths in the salmeterol group.
Pneumonias were more commonly reported in the FSC
250/50 group, reported in 29 (7%) subjects treated with FSC
1106 G.T. Ferguson et al.250/50 compared with 15 (4%) subjects in the salmeterol
group. Serious adverse events of pneumonia were experi-
enced by 19 (5%) and 10 (3%) of subjects in the FSC 250/50
and salmeterol groups, respectively. Adverse events of
dysphonia and candidiasis-related events were reported
for a larger percentage of subjects in the FSC 250/50 group
(4% for each) than in the salmeterol group (<1% and 2%,
respectively). The incidence of eye and bone disorders was
low (1e3%) and reported for a similar number of subjects in
both treatment groups.Discussion
We found that treatment with FSC 250/50 for 1 year signif-
icantly reduced the annual rate of moderate to severe
COPD exacerbations by 30.5% compared with salmeterol.
This finding was consistent with secondary assessments
that showed a significantly lower annual rate of exacerba-
tions requiring oral corticosteroids and a significantly lower
risk of time to first moderate to severe exacerbation with
FSC 250/50 compared with salmeterol. To account for indi-
vidual variation in event rate, the negative binomial analy-
sis was used for analysis of exacerbation rate data.19,20
Finally, pre-dose FEV1 and symptoms scores for dyspnea
were better maintained with FSC 250/50 compared with
salmeterol over the 1-year treatment period.
The findings of this study must be evaluated in the
context of the study design where the patients enrolled
were treated with FSC 250/50 for 4 weeks prior to random-
ization, resulting in withdrawal of FP for patients random-
ized to salmeterol. The purpose of the run-in with FSC
250/50 was to standardize treatment prior to randomiza-
tion in an attempt to minimize the likelihood of exacerba-
tions during run-in related to suboptimal therapy.
Additionally, this design was used to emphasize the contri-
bution of FP to the effect of FSC 250/50 on exacerbations
by comparison with salmeterol. Previous studies have
shown that withdrawal of an inhaled corticosteroid has
been associated with an increase in exacerbation rate, a sig-
nificantly greater risk of time to first and worsening of pul-
monary function and symptoms.21,22 Indeed, the rapid
separation between treatment arms for time to first moder-
ate to severe exacerbation occurred early in this study indi-
cating an increased risk of exacerbation following FP
withdrawal (Fig. 3). Importantly, the difference between
treatments for the probability of experiencing an exacerba-
tion remained consistent throughout the study demonstrat-
ing maintenance of effect for FSC 250/50 compared with
salmeterol.
Additional analyses indicate that the lower exacerbation
rates with FSC 250/50 were not simply due to an inhaled
corticosteroid (ICS) withdrawal effect at the start of the
study. Indeed, the annual rate of moderate to severe
exacerbations was lower with FSC 250/50 compared with
salmeterol even when exacerbations which would more
likely be due to ICS withdrawal (i.e. those occurring in the
first 4 or 8 weeks) were excluded (treatment rate ratios of
0.727, p < 0.001 and 0.751, pZ 0.005, respectively). In ad-
dition, exacerbation rate treatment ratios remained signif-
icantly in favor of FSC 250/50 for the subset of patients not
using inhaled corticosteroids at screening (lower likelihoodof exacerbations being due to ICS withdrawal) (0.740,
pZ 0.028) and in those patients using inhaled corticoste-
roids at screening (higher risk for ICS withdrawal causing
exacerbations) (0.648, p < 0.001).
Other longer term studies have demonstrated the
benefit of FSC at a dose of 500/50 (the higher dose is not
currently approved for use in COPD in the US) on exacer-
bations, each with different study designs.9e11 For exam-
ple, in a 3-year study of COPD patients with an FEV1 of
<60% predicted and with no requirement of a history of
COPD exacerbations, FSC 500/50 significantly reduced the
annual rate of moderate to severe exacerbations compared
with placebo, salmeterol, and FP10 and in a 1-year study of
patients of similar severity to the present study (i.e., post-
bronchodilator FEV1 of <50% with a history of exacerba-
tions) the exacerbation rate was 35% lower with FSC 500/
50 compared with salmeterol.11 In two 6-month studies,
treatment with FSC 250/50 or 500/50 was not shown to re-
duce COPD exacerbations12,23 However, these studies did
not enroll patients at higher risk for exacerbation, as they
were not required to have a history of exacerbations and
exacerbation rates could not be assessed since patients
who received systemic steroids for an exacerbation were
withdrawn. Comparison of the exacerbation findings from
the present study with previous studies, particularly with
regard to dose response, is limited due to differences in
study design. Additionally, the effect of FSC 250/50 on ex-
acerbations in less severe patients requires future study.
Chronic inflammation in the lung is a well-established
characteristic of COPD that is present at all levels of disease
severity, leading to disease pathology and progression.1,2,24
The understanding of COPD-related inflammation has been
expanding to include the presence of systemic inflammation
and exacerbations are associated with further acute in-
creases in both airway and systemic inflammation.25,26 Bac-
terial and viral respiratory tract infections are associated
with the majority of COPD exacerbations27 which is consis-
tent with our study where respiratory infection was identi-
fied as the most common cause of moderate to severe
exacerbations. Infections of the respiratory tract are
thought to be key precipitating events for exacerbations
leading to increased airway neutrophils and eosinophils.27,28
FSC treatment has been shown to have antiinflammatory ef-
fects in COPD29,30 which may provide a potential mechanism
for the reduction in exacerbations observed in our study.
However, the clinical relevance of any effects of FSC 250/
50 on COPD-related inflammation has not been established.
The incidence of pneumonia-related events was higher
in the FSC 250/50 group (7%) compared with the salmeterol
group (4%). These findings confirm previous studies of 1e
3 years showing an increased incidence of pneumonias
with use of FSC 500/50 and FP 500 mg twice daily for
COPD when compared with salmeterol and placebo.10,11 Al-
though limited by study design, a recent retrospective pop-
ulation-based cohort study has suggested that, as a class,
inhaled corticosteroid use in patients with COPD may be
associated with an increased risk of hospitalization for
pneumonia.31,32 The comparative risk of pneumonia be-
tween FSC 250/50 and 500/50 is unknown since there are
no studies that directly compare the two strengths and
due to differences in study design and methodology for de-
termining pneumonia across individual studies. Additional
Fluticasone propionate/salmeterol vs salmeterol for COPD exacerbations 1107prospective studies using objective pneumonia definitions
and detailed clinical, microbiological, and imaging evalua-
tions are required to further characterize the risk of pneu-
monia with FSC in COPD.
The overall incidence of adverse events during treat-
ment was high, as expected for a study of 1 year in a severe
patient population, and the number of subjects with ad-
verse events was similar between groups. The incidence
of known local side effects of inhaled corticosteroids such
as oral candidiasis and dysphonia occurred more frequently
with FSC 250/50 than salmeterol. Systemic effects of FSC
250/50 were not apparent based on a similar incidence of
adverse events related to eye and bone disorders in the
FSC 250/50 and salmeterol groups.
In summary, this is the first study specifically designed to
evaluate the effect of FSC 250/50 mg twice daily on exacer-
bations of COPD. Long-term treatment with FSC 250/50
was shown to result in a significantly lower annual rate of
moderate to severe exacerbations compared with the long-
acting beta-agonist salmeterol in patients with severe
COPD with a history of exacerbations. Additionally, a higher
incidence of reported pneumonia was observed with flutica-
sone propionate/salmeterol 250/50 than salmeterol. This
study provides further information on the effectiveness
and safety of FSC 250/50 for the treatment of COPD.Acknowledgements
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